The New Face of Alcoholism Treatment Brain Energy Management: THE FIRST CLINICAL TREATMENT OF Metabolic Brain Cell Disease Type Basal Ganglia

This highly valuable manuscript identifies Metabolic Brain Cell Disease Type Basal Ganglia (MBCD-BG) as the elusive culprit behind alcoholism, proposes treatment and presents the first clinical study of this disease using the FiX-Zy Oil. Dr. Roger Hershline PHD MD, discoverer of MBCD-BG, inventor of the FiX-Zy OiL and founder of Global Humanceuticals Inc. presents valuable insights into what the future treatment of alcoholism should be and will be. Sufferers for the first time will be treated with appropriate medical knowledge and protocol. No longer will the alcoholic be shamed, blamed and abandoned. The treatment of alcoholism requires the understanding of the underlying diabetic-like condition of the control center of the brain and the need to supplement the diet with a special diet. Also, because the proper functioning of the Cerebral Cortex, Limbic system, and the Fight or Flight center of the brain stem requires proper signals form the control center, many symptoms are present in the abstinent alcoholic such as thought derangement, irritabilty and anxiety. Only if these symptoms resolve can the alcoholic remain sober. These symptoms can only be resolved with the improved functioning and release of neurotransmitters from the Basal Ganglia resulting from the special diet. Dr. Roger Hershline predicts that central nervous system neuronal glucose transporters will be discovered and that these transporters have a genetically based abnormality in the alcoholic and with Metabolic Brain Cell Disease Type Basal Ganglia. Dr. Hershline has conducted the first clinical trial to demonstrate the reality of alcoholism and how best to treat this lethal disease. Much insight is provided along with the personal stories of many of the actual clinical study participants.